Incidental hepatic regenerating nodules rarely occur after haematopoietic SCT (HSCT). Focal nodular hyperplasia (FNH) is one of these unusual benign tumors with characteristic imaging features. To determine the incidence and the outcome of FNH of the liver and improve the understanding of its pathogenesis, we prospectively surveyed a total of 138 patients who had undergone serial prospective pre- and post-transplantation evaluations of iron biomarkers, including ferritin and liver iron concentration assessed by magnetic resonance imaging (MRI). Seventeen patients with a median delay of 6.4 years (2.2-13.6) developed FNH of the liver. All were children at the time of transplantation. MR images were typical for FNH in 16 patients; only one patient needed a confirmatory biopsy. Sixteen had received a myeloablative conditioning; six received a BU-based preparation and 10 TBI. Three patients experienced sinusoidal obstruction syndrome. Neither complication nor malignant transformation has been reported to date. FNH of the liver seems to be a frequent delayed benign complication following HSCT, probably of iatrogenic vascular origin. Basic clinical and diagnostic imaging follow-up is warranted.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/bmt.2008.304 | DOI Listing |
World J Gastroenterol
January 2025
Department of Radiology, Kindai University, Faculty of Medicine, Osakasayama 589-8511, Osaka, Japan.
Background: Focal nodular hyperplasia (FNH)-like lesions are hyperplastic formations in patients with micronodular cirrhosis and a history of alcohol abuse. Although pathologically similar to hepatocellular carcinoma (HCC) lesions, they are benign. As such, it is important to develop methods to distinguish between FNH-like lesions and HCC.
View Article and Find Full Text PDFQuant Imaging Med Surg
December 2024
Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Background: Focal nodular hyperplasia (FNH) in the liver is a benign lesion and the relationship between lesion size and imaging features is yet to be established. We aimed to develop and validate a scoring system to assess the relationship between magnetic resonance imaging (MRI) features and lesion size in FNH.
Methods: This cross-sectional study was conducted at Zhongshan Hospital, Fudan University in Shanghai, China, from August 2019 and March 2023.
Front Nucl Med
November 2024
Department of Radiology, Mayo Clinic, Rochester, MN, United States.
Eur Radiol Exp
December 2024
Department of Interventional Ultrasound, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Fengtai District, Beijing, 100853, China.
Background: Noninvasive and functional imaging of the focal liver lesion (FLL) vasculature at microscopic scales is clinically challenging. We investigated the feasibility of using super-resolution ultrasound (SR-US) imaging for visualizing and quantifying the microvasculature of intraparenchymal FLLs.
Methods: Patients with FLLs between June 2022 and February 2023 were prospectively screened.
Ultrasound Q
December 2024
Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN.
Magnetic resonance imaging (MRI) may be time-consuming, expensive, or poorly tolerated by patients with liver lesions. This is a prospective clinical trial designed to evaluate if contrast-enhanced ultrasound (CEUS) can be used to differentiate focal nodular hyperplasia (FNH) from hepatocellular adenoma (HCA) with similar accuracy compared with hepatobiliary agent MRI.Institutional review board approval was obtained (1805450097), and the trial was registered with ClinicalTrials.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!